<i>In Vitro</i> Activity of Manogepix against Multidrug-Resistant and Panresistant Candida auris from the New York Outbreak
YanChun Zhu, Shannon Kilburn, Mili Kapoor, Sudha Chaturvedi, Karen Joy Shaw, Vishnu Chaturvedi
Abstract
An ongoing Candida auris outbreak in the New York metropolitan area is the largest recorded to date in North America. Laboratory surveillance revealed NY C. auris isolates are resistant to fluconazole, with variable resistance to other currently used broad-spectrum antifungal drugs, and that several isolates are panresistant. Thus, there is an urgent need for new drugs with a novel mechanism of action to combat the resistance challenge. Manogepix (MGX) is a first-in-class agent that targets the fungal Gwt1 enzyme.
Topics & Concepts
Candida aurisFluconazoleOutbreakMicrobiologyMultiple drug resistanceBiologyVirologyAntifungalDrug resistanceAntifungal resistance and susceptibilityFungal Infections and StudiesSynthesis and Biological Evaluation